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Summary Between 1982 and 1991, 41 patients were treated for non HIV related primary cerebral lymphoma
(PCL) in our institute. The purpose of this study was to perform a multivariate analysis of prognostic factors
for survival in these patients. The presence of a CSF protein level over 0.6 g 1-' at diagnosis was found to be
the most significant unfavourable prognostic factor in univariate analysis and had not previously been
reported. Among the five significant prognostic factors at diagnosis, (age over 60 years, performance status -
ECOG scale - over 2, memory dysfunction, non hemispheric tumour site, CSF protein level over 0.6 g 1' at
the diagnosis), three independent factors were identified in multivariate analysis: (I) CSF protein level
(P = 0.007; RR = 4.7); (2) PS>2 (P = 0.04, RR = 2.65); (3) age over 60 (P = 0.08; RR = 2.43). Using the
regression coefficient of these three parameters, we determined a prognostic index which allowed us to
distinguish three risk groups whose theoretical median survival is 4, 20 and 54, months respectively in patients
with non HIV related PCL. These results indicate that PCL is an heterogenous disease in terms of the
prognostic in which three subgroups with discriminant survival can be identified.
Primary cerebral lymphoma (PCL) is a rare neoplasm
accounting for approximately 0.7% of all lymphoma and less
than 2% of all brain tumours (Henry et al., 1974; Levitt et
al., 1980; Woodman et al., 1985; Murray et al., 1987; Hoch-
berg & Miller, 1988). The incidence of PCL is significantly
increased in patients with severe immunodeficiency including
acquired immunodeficiency syndrome (AIDS) (Snyder et al.,
1983; Gill et al., 1985). Recent reports indicate that the
incidence of PCL is also increasing in apparently non-
immunodeficient subjects, although the reason for these
observations remains obscure (Eby et al., 1988). In contrast
to other non Hodgkin's lymphomas (Canellos et al., 1987;
Coiffer et al., 1989; Longo et al., 1991; Patte et al., 1991),
PCL has a poor prognosis in most of the series with treat-
ment combining surgery with chemotherapy and/or
radiotherapy (Murray et al., 1987; Hochberg & Miller, 1988;
Berry et al., 1981; Letendre et al., 1982; Gonzales-Gonzales
et al., 1983; Freeman et al., 1986). However, intensive
chemotherapy regimens including drugs that pass the blood-
brain barrier appear to give improved results in recently
published trials (De Angelis et al., 1990; Neuwelt et al., 1991;
De Angelis et al., 1992). Neuwelt et al. (1991) have described
a regimen containing high dose methotrexate (HDMTX) and
two alkylating agents given wtih osmotic blood-brain barrier
disruption which yields a projected 40% survival and at 3
years. De Angelis et al. (1992) have reported a regimen
combining HDMTX, cytosine arabinoside and cranial
irradiation which yields 35% survival at 4 years.
Since PCL is a rare neoplasm, most of the series include a
limited number of patients and the optimal treatment re-
mains to be defined. Furthermore, comparison of therapeutic
results between studies is complicated by the differences in
the clinical presentations of this disease and the lack of
knowledge of prognostic factors. Several univariate analyses,
most involving less than 30 patients, have identified prognos-
tic factors for survival in patients with PCL )Loeffler et al.,
1985; Murray et al., 1986; Mendenhall et al., 1986; Pollack et
al., 1989; Michalski et al., 1990). Some of these prognostic
factors are identical to those previously shown for aggressive
lymphomas not involving the CNS, such as age, performance
status at diagnosis, size of the lesion, and serum LDH levels.
Specific prognostic factors for PCL, such as confinement of
the tumour to cerebral hemispheres and extension of the
tumour outside the brain have also been reported (Murray et
al., 1986; Loeffler et al., 1985; Pollack et al., 1989; Michalski
et al., 1990). Among therapeutic features, the dose of radia-
tion (Murray et al., 1986; Berry & Simpson, 1981; Pollack et
al., 1989; Brada et al., 1990) and treatment with
chemotherapy (Pollack et al., 1989; Michalski et al., 1990;
Shibamato et al., 1989) have been shown to correlate with
survival. To date, however, no multivariate analysis of prog-
nostic factors for survival in PCL has been reported.
Here, we report a retrospective analysis of 41 non-HIV
non immunodeficient patients with PCL treated at the Centre
Leon Berard in Lyon between 1982 and 1991. Three indepen-
dent,prognostic criteria were identified using the Cox model.
We have determined an algorithm of relative risk which
allows the identification of three different risk groups with a
discriminant projected survival.
Patients and methods
Patients
Between 1982 and 1991, 46 patients with a non-HIV related
PCL were recorded at the Centre Leon Berard (CLB). None
of these patients had a known cause of immunodeficiency.
Five of these 46 patients were referred only for radiotherapy
or follow-up after an initial treatment performed outside of
our institute and were not included in this analysis because of
its insufficient data concerning their initial clinical status.
Thus, 41 patients with PCL were diagnosed and treated at
the CLB between 1982 and 1991. In 37 patients, HIV
serology was performed and found negative. Four patients
were not tested for HIV but none of them belonged to the
previously reported risk groups and none had lymphopenia
or experienced opportunistic infections. The clinical charac-
teristics of these 41 patients are presented in Table I. All
lymphomas were intermediate or high grade lymphomas with
a majority of diffuse large cell lymphoma (47%). In most of
the patients (85%), the tumour was confined to the brain.
Four patients (10%) also had an ocular involvement diag-
nosed before (n = 1), synchronously (n = 2) or after (n = 1)
the brain tumour as previously reported (Murray et al., 1988;
Hochberg & Simpson, 1988). One of the patients (5%) had a
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Table I Characteristics of the patients
Age: median (range)
Sex: (H/F)
Performance status: median (range)
Histological subtype (Working Formulation
F: diffuse mixed cells
G: diffuse large cells
H: immunoblastic
I: lymphoblastic
J: small non cleaved
Stage at the diagnosis
Only CNS
Meningeal involvement
Multifocal brain tumour
Ocular and CNS
Bone marrow and lymph nodes
involvement:
Initial surgical treatment
Complete resection
Partial resection
Biopsy
Post surgical treatment
Radiotherapy alone
Chemotherapy
COPADEM/CYV
MBACOD
CVP
LNH87 protocol
mBACOD
ACVBP/VIM3
CVP/CTVP
Radiotherapy
Dose on the whole brain over 40 Gy
Dose on the whole brain over 50 Gy
Site of documented relapse
Primary brain site
Multiple brain sites
Meningeal involvement
Intra ocular relapse
Non CNS/ocular relapse
Number of patients
59 (14-77)
30/11
2 (0-4)
7
18
13
1
2
38
2
5
2
1
4
15
22
3
38
9
7
4
2
12
4
27
9
2
20
12
8
4
2
0
phamide, vindesine, prednisone, intrathecal methotrexate) or
two courses ofACVBP alternating with two courses ofVIM3
(etoposide, ifosfamide, high dose methotrexate, mitoxan-
throne, mitoguazone, intrathecal methotrexate) followed by a
consolidation treatment with two courses of high dose
methotrexate, cytosine arabinoside, asparaginase, ifosfamide,
etoposide. The two patients with meningeal involvement
received nine intrathecal injections of methotrexate and/or
cytosine arabinoside.
The three remaining patients were treated with radio-
therapy only because of patient refusal. Relapses were
evidenced by CT scan in 20 patients. Twelve (60%) of the 20
documented relapses occurred only at the primary brain site
whereas eight (40%) patients had multifocal brain relapse.
Two patients (4%) experienced ocular relapse. None of the
patients relapsed outside the central nervous system (CNS).
Methods
Statistical analyses were carried out according to the proce-
dures of the BMDP package. The Chi square test was used
to compare the distribution of the different parameters
between the subgroups of patients. The survival curves were
generated by the Kaplan-Meier method (Kaplan & Meier,
1958). Survival times were measured from the date of the
histological diagnosis of the lymphoma to the date of death
or the date of the last follow-up of patients still alive. The
log-rank test was used to compare the distribution of survival
times in univariate analysis and to select statistically
significant factors. Then, a multivariate analysis was per-
formed using the Cox proportional hazard model (Cox,
1972). Backwards regression selection procedure was used to
identify the significant prognostic factors. Relative risks were
expressed as the ratio of relative death rate into two groups
(Oi/Ei, O:observed), E:expected). The relative risks of these
prognostic factors were used to create an algorithm which
made it possible to separate the patients into three distinct
risk groups. Using the regression coefficinet estimated in the
Cox model for each variables, covariate scores were cal-
culated for each patient. These results were used to construct
the theoretical survival in the three discriminant risk groups.
primary cerebral large cell lymphoma associated with a small
lymphocytic lymphoma of lymph nodes and bone marrow
(Table I); this patient died of PCL progression after
chemotherapy while in complete remission of the small lym-
phocytic lymphoma.
Macroscopic complete and partial surgical resections were
performed in four (10%) and 15 (37%) patients respectively.
Twenty-two (53%) patients underwent only a tumour biopsy
for diagnosis. Thirty-eight of the 41 patients (92%) received
chemotherapy as first line therapy after surgery. Twenty-
seven of these received cranial radiotherapy after chemo-
therapy. The 11 remaining patients died during chemo-
therapy before the initiation of radiotherapy. Chemotherapy
regimens given to these patients were as follows. The short
arm of the LMB chemotherapy program (Patte et al., 1991)
including five courses of chemotherapy (cyclophosphamide,
doxorubicin, vincristine, prednisone, cytosine-arabinoside,
high dose methotrexate, seven intrathecal injections of
methotrexate, two intrathecal injections of cytosine arabino-
side) was given to all the patients under 50 years of age
(n = 9). Patients over 70 (n = 5) received six courses of CTVP
(cyclophosphamide 750 mg m-2 dl, pirarubicin 50 mg k-2 dl,
teniposide 75 mg m-2 dl, methylprednisone 40 mg m-2 dl-3).
Before 1987, eight courses of the m/MBACOD regimen (high
dose methotrexate, bleomycin, doxorubicin, cyclophos-
phamide, vincristine, dexamethasone) were given to the seven
patients above 50 years of age (Canellos et al., 1987). After
1987, all patients above 50, were included in the LNH87
protocol (n = 17) (Coiffier et al., 1989). This program con-
tained an induction chemotherapy sequence with either four
courses of ACVBP (bleomycin, doxorubicin, cylcophos-
Results
With a median follow up of 30 months, the projected overall
survival is 22% and the median survival is 20 months (Figure
1). Clinical and biological prognostic factors for survival
were analysed (Table II). Five parameters were found to have
an unfavourable prognostic value: (a) non hemispheric
tumour location i.e. involvement of corpus callosum or sub-
cortical grey structures (P = 0.03), (b) age over 60 (P<0.01),
(c) memory dysfunction (P<0.01), (d) initial performance
status (PS) over 2 on the ECOG scale (P = 0.001) and (e)
presence of a cerebrospinal fluid (CSF) protein level over
0.6 g 1-', at the diagnosis (P<0.001). The latter criterion was
found to be the most significant unfavourable prognostic
factor (Table II). No differences for time to relapse, site of
relapse or survival rates were observed according to the
different surgical procedures or the total dose of radiation
given to the whole brain (Table II). Survival was not
significantly different between the chemotherapy regimens,
i.e. the LMB program, LNH87, m/MABCOD and CTVP
(data not shown).
Significant (P<0.05) prognostic factors for survival were
selected for the multivariate analysis (Table II). Only CSF
protein level, performance status and age were found to be
independent determinants of survival (Table III). The two
remaining prognostic factors, i.e. hemispheric location and
memory dysfunction were strongly correlated to both CSF
protein level and performance status (P<0.01) and were
thus eliminated by the regression procedure. The relative
risks of performance status and age were similar in magni-
tude (relative risk (RR): 2.43 and 2.65) and close to half of1138 J.-Y. BLAY et al.
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Figure 1 Overall survival of the 41 patients with primary cerebral lymphoma treated at the Centre Leon Berard between 1982 and
1991.
Table II Prognostic factors in univariate analysis
Number of Median Logrank
patients survival (P value)
Age
<60 21 42
>60 20 19 8.84 (<0.01)
Performance status
(ECOG)
0-2 22 38
3-4 19 4 10.66 (0.001)
Impaired memory
N 21 57
y 20 7 9.75 (<0.01)
Strictly hemispheric tumour
Y 22 23
N 19 13 4.70 (0.03)
CSF protein <0.6 g 1'
N 25 7
y 16 56 12.05 (<0.001)
Surgery (resection)
Complete 4 20
Partial; 15 16 <1 (NS)
Biopsy 22 20
Dose of radiotherapy
<40Gy 18 42
>40Gy 9 22 1.48 (NS)
<50Gy 25 38
>50 Gy 2 13 <1 (NS)
Y: yes; N: No; NS: not significant.
Table III Independent variables in multivariate analysis
Regression
coefficient Standard Relative
(1) error of P risk (e-) P value
CSF protein over 1.56 0.57 4.75 0.007
0.6gl-
PS>2 0.97 0.48 2.65 0.04
Age over 60 0.91 0.51 2.48 0.08
the relative risk associated with increased CSF protein level
(RR: 4.69) (Table III). In order to construct a simple
algorithm for calculating the expected risk of deaths for each
patient, the parameters 'age over 60', 'PS over 2', 'CSF
protein over 0.6 g 1-" were given an arbitrary risk coefficient
of respectively 1, 1 and 2. These coefficients enable one to
generate a theoretical risk index, ranging from 0 to 4,
obtained by summing the coefficients of these three risk
factors. For instance, a patient aged 56 with PS = 3, CSF
protein level 0.98 has a risk index of 3. A 65 year old patient
with PS = 1 and CSF protein level 0.45 has a risk index of 1.
This risk index permitted us to define three risk groups with
a risk index value under 2, equal to 2 and over 2 respectively
(Table IV). Covariate scores were calculated as indicated in
materials and methods for the different combinations of the
three parameters and usef for the construction of theoretical
survival of the three risk groups. These three risk groups
have a simulated median survival of 54, 20 and 4 months and
include 25% (n = 10), 36% (n = 15) and 39% (n = 16) of the
patients of this series respectively. The simulated and
observed survival curves of these three risk groups are shown
in Figure 2.
Table IV Description of the risk index and risk subgroups
Prognostic CSF Pr Risk
group <0.6gl' PS<3 Age<60 index N (%)
1 Y Y Y 0
Y N Y 1 10 (25)
Y Y N 1
2 N Y Y 2 15 (36)
Y N N 2
3 N Y N 3
N N Y 3 16 (39)
N N N 4
Y: yes; N: no.PROGNOSTIC INDEX IN PRIMARY CEREBRAL LYMPHOMA
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Figure 2 Curves 1,2,3 correspond to the observed survival in patients from risk group 1, 2 and 3. Curves A,B,C correspond to the
theoretical survival of patients from risk group 1, 2 and 3 according to the model.
Discussion
The aim of this study was to determine independent prognos-
tic factors for survival in PCL and to distinguish prognostic
subgroups. This series includes 41 patients with non HIV
PCL treated in our institution since 1982 and thus represents,
given the low incidence of PCL, a relatively large group of
PCL for a single institution. Survival in this series is com-
parable to that previously reported in the literature for PCL
(Murray et al., 1987; Hochberg & Miller, 1988). Our data
confirm previous observations indicating that age, perfor-
mance status, and hemispheric location of the tumour are
prognostic factors in PCL (Murray et al., 1986; Mendenhall
et al., 1986; Loeffler et al., 1985; Pollack et al., 1989; Michal-
ski et al., 1990). We found two previously unidentified prog-
nostic factors i.e. memory loss and CSF protein level over
0.6 g 1-, the latter being the most unfavourable prognostic
predictor in univariate analysis. The cut-off value of 0.6 g
corresponds to 150% of the upper normal value of CSF
protein and was chosen because it clearly identifies patients
with abnormal CSF protein. The significance of CSF protein
level as a prognostic factor remains unclear. Increased CSF
protein levels were observed in patients whose tumour were
located close to the ventricles and involved corpus callosum
or subcortical grey structures. Conceivably, CSF protein level
could indicate an infraclinical meningeal involvement ana
thus reflect the aggressiveness of the tumour. Histological
subtypes (I,J subtypes) and serum LDH levels are well-
knonw prognostic parameters for NHL; these factors have
not been considered for univariate analysis because of the
very low number of patients with significantly increased
serum LDH as well as in the I or J histological subgroups.
Only CSF protein level, performance status and age were
independent prognostic factors. Memory loss and non-
hemispheric tumour location were highly correlated and both
parameters also strongly correlated to CSF protein level.
These two factors were thus rejected by the regression proce-
dure. The three independent parameters enabled us to
generate a simple algorithm for distinguishing three prognos-
tic subgroups with very different survivals. This notion of
combining subsets of patients is similar to the strategies used
to define risk groups in patients with thyroid carcinoma
(Byar et al., 1979) and renal cell carcinoma (Elson et al.,
1988) and can be easily used for medical decision making.
The most favourable group, risk group 1, has a theoretical
median survival of 54 months after the diagnosis whereas
risk group 3 has a median survival of4 months. These results
point out that subgroups with a completely different prog-
nosis can be identified among patients with PCL. Recently, a
prognostic index has been reported in NHL using a database
of 3273 patients (Shipp et al., 1992). The classification of the
41 PCL patients of our series according to this prognostic
index did not distinguish the subgroup of good prognosis
(25% of the patients) described in our model (personal
unpublished results), indicating that PCL could require a
distinct prognostic index.
In this study, the same data were used to derive and verify
the index; it will thus be interesting to test the value of this
model in another large series of patients with PCL. Retro-
spective comparisons of different treatments for PCL could
take such a model in account in order to analyse results
between comparable subgroups of patients. These prognostic
subgroups could also be considered for stratification in future
clinical trials.
We have tried to analyse the role of the different thera-
peutic procedures in this series according to the prognostic
index. These observations are of course only indicative since
the effect of treatments can only be assessed in a prospective
manner. Doses of radiotherapy over 50 Grays (Gy) have
previously been associated with an improved survival com-
pared to lower doses (Murray et al., 1986; Berry et al., 1983).
No correlation between the dose ofradiotherapy and survival
was observed in this series. Neither of the two patients who
received such doses was alive 20 months after the diagnosis.
Furthermore, among four long term (over 4 years disease-
free) survivors, three received less than 40 Gy to the whole
brain. Also, all these patients belonged to risk group 1. This
suggests that, at least for risk group 1, high doses of
radiotherapy to the whole brain may not be necessary to
achieve long term disease control. However, most relapses
occurred at the primary brain site. It could be valuable to
study radiotherapy protocols giving a high dose (> 50 Gy) to
the tumour bed and a reduced dose to the whole brain in risk
groups 2 and 3.
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The association of chemotherapy and radiotherapy after
surgery has been reported to yield better results than
radiotherapy alone (Pollack et al., 1989; Michalski et al.,
1990; Shibamato et al., 1989) although this has not con-
sistently been found (Murray et al., 1986). An important
point is whether a reduction of chemotherapy intensity in
patients over 60 years may be responsible for the worse
survival in this subgroup. Most of the regimens used in these
patients (see Materials and methods) included high dose
methotrexate and/or ARA-C, two drugs previously reported
to be highly efficient in PCL (Neuwelt et al., 1991; de Angelis
et al., 1992). Actually, no significant differences in terms of
survival were observed between the different chemotherapy
regimens used in this study, including CTVP (not shown) but
the low number of patients in each subgroup limit the value
of this observation. Furthermore, patients between 50 and 70
years old received the same chemotherapy regimens. It is thus
unlikely that the correlation between age and prognostic is
due to a reduction of treatment intensity in patients older
than 60.
The radiotherapy and chemotherapy protocols used in this
study are clearly unable to provide a long term tumour
control in most of the patients not belonging to risk group 1.
It is noteworthy that all the 5 year survivors belong to risk
group 1, a subgroup of patients with 4 year survival of 57%
which represents only 25% of our population. Only a small
number of patients from risk group 2 and 3, if any, can
achieve long term survival. These results indicate that
patients from risk group 1 require different therapeutic pro-
cedures than patients from risk group 2 and 3 and that
current treatments have a poor efficacy in patients who do
not belong to risk group 1.
This work was supported by grants from the Comite de la Savoie,
Comite de la Drome de la Ligue contre le Cancer, La Region
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